Sight Diagnostics

The problem: a blood count that requires a central lab

A complete blood count (CBC) is one of the most common blood tests, but with the traditional method the result is delayed by hours or even days because it depends on a central lab. Sight Diagnostics, founded in 2011 by Yossi Pollak (CEO) and Dr. Daniel Levner, developed a compact device (OLO) that performs the test at the point of care, from a small drop of blood, using computer vision and artificial intelligence that analyze more than 1,000 detailed images for each sample.

OLO: FDA clearance and funding

At the end of 2019 OLO received 510(k) clearance from the FDA for use in moderate-complexity labs, alongside the European CE mark and Australian TGA approval for point-of-care use. In August 2020 the company announced a $71 million Series D round, with Koch Disruptive Technologies, Longliv Ventures (part of the CK Hutchison group) and OurCrowd, a round that brought its total funding to more than $124 million. The company also worked with Pfizer and with hospitals such as Sheba Tel Hashomer.

Laying off all employees in 2026

Despite the funding it raised and its industry recognition (including a place on CNBC's Disruptor 50 list for 2021, a bronze award in the Medical Design Excellence Awards according to the company's own report, an honorable mention in Fast Company's "World Changing Ideas", and a quarterfinal place in UC San Francisco's digital health awards), Sight Diagnostics did not manage to achieve commercial profitability. According to an April 2026 report, the company's board laid off all of the roughly 20 employees who remained, after a series of layoffs and downsizing in the preceding years, down from a peak of more than 150 employees. The company declined to comment on the report, which left it on the brink of full closure.